142 related articles for article (PubMed ID: 23570792)
1. SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors.
Karra S; Xiao Y; Chen X; Liu-Bujalski L; Huck B; Sutton A; Goutopoulos A; Askew B; Josephson K; Jiang X; Shutes A; Shankar V; Noonan T; Garcia-Berrios G; Dong R; Dhanabal M; Tian H; Wang Z; Clark A; Goodstal S
Bioorg Med Chem Lett; 2013 May; 23(10):3081-7. PubMed ID: 23570792
[TBL] [Abstract][Full Text] [Related]
2. Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
Kim KH; Wissner A; Floyd MB; Fraser HL; Wang YD; Dushin RG; Hu Y; Olland A; Guo B; Arndt K
Bioorg Med Chem Lett; 2009 Sep; 19(17):5225-8. PubMed ID: 19628388
[TBL] [Abstract][Full Text] [Related]
3. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a highly selective inhibitor of the Aurora kinases.
Ferguson FM; Doctor ZM; Chaikuad A; Sim T; Kim ND; Knapp S; Gray NS
Bioorg Med Chem Lett; 2017 Sep; 27(18):4405-4408. PubMed ID: 28818446
[TBL] [Abstract][Full Text] [Related]
5. Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
Abraham S; Hadd MJ; Tran L; Vickers T; Sindac J; Milanov ZV; Holladay MW; Bhagwat SS; Hua H; Ford Pulido JM; Cramer MD; Gitnick D; James J; Dao A; Belli B; Armstrong RC; Treiber DK; Liu G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5296-300. PubMed ID: 21802948
[TBL] [Abstract][Full Text] [Related]
6. Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.
Wang Y; Xu ZL; Ai J; Peng X; Lin JP; Ji YC; Geng MY; Long YQ
Org Biomol Chem; 2013 Mar; 11(9):1545-62. PubMed ID: 23188156
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
8. 3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.
Morioka M
Bioorg Med Chem Lett; 2016 Dec; 26(24):5860-5862. PubMed ID: 27884697
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as aurora kinase inhibitors.
Defaux J; Antoine M; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
ChemMedChem; 2014 Jan; 9(1):217-32. PubMed ID: 24273104
[TBL] [Abstract][Full Text] [Related]
10. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.
Heron NM; Anderson M; Blowers DP; Breed J; Eden JM; Green S; Hill GB; Johnson T; Jung FH; McMiken HH; Mortlock AA; Pannifer AD; Pauptit RA; Pink J; Roberts NJ; Rowsell S
Bioorg Med Chem Lett; 2006 Mar; 16(5):1320-3. PubMed ID: 16337122
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Howard S; Berdini V; Boulstridge JA; Carr MG; Cross DM; Curry J; Devine LA; Early TR; Fazal L; Gill AL; Heathcote M; Maman S; Matthews JE; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Rees DC; Reule M; Tisi D; Williams G; Vinković M; Wyatt PG
J Med Chem; 2009 Jan; 52(2):379-88. PubMed ID: 19143567
[TBL] [Abstract][Full Text] [Related]
12. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
[TBL] [Abstract][Full Text] [Related]
13. SAR156497, an exquisitely selective inhibitor of aurora kinases.
Carry JC; Clerc F; Minoux H; Schio L; Mauger J; Nair A; Parmantier E; Le Moigne R; Delorme C; Nicolas JP; Krick A; Abécassis PY; Crocq-Stuerga V; Pouzieux S; Delarbre L; Maignan S; Bertrand T; Bjergarde K; Ma N; Lachaud S; Guizani H; Lebel R; Doerflinger G; Monget S; Perron S; Gasse F; Angouillant-Boniface O; Filoche-Rommé B; Murer M; Gontier S; Prévost C; Monteiro ML; Combeau C
J Med Chem; 2015 Jan; 58(1):362-75. PubMed ID: 25369539
[TBL] [Abstract][Full Text] [Related]
14. AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.
Juan G; Bush TL; Ma C; Manoukian R; Chung G; Hawkins JM; Zoog S; Kendall R; Radinsky R; Loberg R; Friberg G; Payton M
J Transl Med; 2014 Nov; 12():307. PubMed ID: 25367255
[TBL] [Abstract][Full Text] [Related]
15. A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.
Rawson TE; Rüth M; Blackwood E; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Georges GJ; Goller B; Halladay J; Hunsaker T; Kleinheinz T; Krell HW; Li J; Liang J; Limberg A; McNutt A; Moffat J; Phillips G; Ran Y; Safina B; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhou A; Zhu BY; Rüger P; Cochran AG
J Med Chem; 2008 Aug; 51(15):4465-75. PubMed ID: 18630890
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity.
Voss ME; Rainka MP; Fleming M; Peterson LH; Belanger DB; Siddiqui MA; Hruza A; Voigt J; Gray K; Basso AD
Bioorg Med Chem Lett; 2012 May; 22(10):3544-9. PubMed ID: 22503250
[TBL] [Abstract][Full Text] [Related]
18. Discovery of dibenzo[c,f][2,7]naphthyridines as potent and selective 3-phosphoinositide-dependent kinase-1 inhibitors.
Gopalsamy A; Shi M; Boschelli DH; Williamson R; Olland A; Hu Y; Krishnamurthy G; Han X; Arndt K; Guo B
J Med Chem; 2007 Nov; 50(23):5547-9. PubMed ID: 17941624
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
20. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
